{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T00:02:39Z","timestamp":1648857759888},"reference-count":28,"publisher":"American Society of Consultant Pharmacists","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Consultant Pharmacist"],"published-print":{"date-parts":[[2004,6,1]]},"DOI":"10.4140\/tcp.n.2004.524","type":"journal-article","created":{"date-parts":[[2011,1,13]],"date-time":"2011-01-13T02:08:00Z","timestamp":1294884480000},"page":"524-532","source":"Crossref","is-referenced-by-count":0,"title":["Impact of New-Generation Agents on Antiepileptic Drug Prescribing Patterns in a Residential ICF-MR Facility"],"prefix":"10.4140","volume":"19","author":[{"given":"Stacey Allison","family":"Smith","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerry R.","family":"McKee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2625","published-online":{"date-parts":[[2009,7,9]]},"reference":[{"key":"1","doi-asserted-by":"crossref","DOI":"10.1017\/S0317167100034892","article-title":"Monotherapy or polytherapy for epilepsy?","volume":"25","author":"A. Guberman","year":"1998","journal-title":"Can J Neurol Sci"},{"key":"2","first-page":"563","article-title":"Combination therapy (monotherapy versus polytherapy)","volume-title":"Pediatric epilepsy \u2014 diagnosis and therapy","author":"B Buorgeois","year":"2001"},{"key":"3","article-title":"Monotherapy and polypharmacy","volume":"55","author":"I Leppik","year":"2000","journal-title":"Neurology"},{"key":"4","article-title":"Changes in antiepileptic drug prescribing patterns in large institutions: preliminary results of a five-year experience","volume":"38","author":"A Poindexter","year":"1993","journal-title":"AJMR"},{"key":"5","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1007\/BF03259239","article-title":"Results of antiepileptic drug reduction in patients with multiple handicaps and epilepsy","volume":"5","author":"W Mirza","year":"1993","journal-title":"Drug Invest"},{"key":"6","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0920-1211(02)00182-1","article-title":"Overtreatment in epilepsy: adverse consequences and mechanisms","volume":"52","author":"E Perucca","year":"2002","journal-title":"Epilepsy Res"},{"key":"7","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/j.1528-1157.1983.tb04900.x","article-title":"Reduction of two-drug therapy in intractable epilepsy","volume":"24","author":"D Schmidt","year":"1983","journal-title":"Epilepsia"},{"key":"8","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1136\/jnnp.45.12.1119","article-title":"Two antiepileptic drugs for intractable epilepsy with complex partial seizures","volume":"45","author":"D. Schmidt","year":"1982","journal-title":"J Neurol Psychiatry"},{"key":"9","article-title":"Epilepsy: Diagnosis, Management, Quality of Life","year":"1985"},{"key":"10","first-page":"209","article-title":"Antiepileptic and neuro-toxic interactions between antiepileptic drugs","volume-title":"Antiepileptic Drug Interactions","author":"B Buorgeois","year":"1989"},{"key":"11","doi-asserted-by":"crossref","DOI":"10.1111\/j.1528-1157.1997.tb04536.x","article-title":"Comprehensive management of epilepsy in persons with mental retardation","volume":"38","author":"D Coulter","year":"1997","journal-title":"Epilepsia"},{"key":"12","doi-asserted-by":"crossref","DOI":"10.1177\/0883073897012001091","article-title":"Meeting the challenge of epilepsy in persons with multiple handicaps.","volume":"12","author":"T Sunder","year":"1997","journal-title":"J Child Neurol"},{"key":"13","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/1098-2779(2000)6:4<309::AID-MRDD10>3.0.CO;2-I","article-title":"Treatment of epilepsy in the multiply handicapped","volume":"6","author":"J Pellock","year":"2000","journal-title":"Ment Retard Dev Dis Res Rev"},{"key":"14","article-title":"Use of antiepileptic drugs in the treatment of epilepsy in people with intellectual disability","volume":"42","author":"N Alverez","year":"1998","journal-title":"J Intell Dis Res"},{"key":"15","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0010-440X(97)90072-9","article-title":"Mental disorder in adults with mental retardation and epilepsy","volume":"38","author":"S Deb","year":"1997","journal-title":"Comp Psych"},{"key":"16","first-page":"3","article-title":"Rational polypharmacy","year":"1996"},{"key":"17","first-page":"228","article-title":"Clinical pharmacy services in an intermediate care facility for the mentally retarded","volume":"29","author":"J McKee","year":"1994","journal-title":"Hosp Pharm"},{"key":"18","first-page":"1392","article-title":"Clinical pharmacy services in an intermediate care facility for the developmentally disabled: a five-year retrospective review","volume":"14","author":"J McKee","year":"1999","journal-title":"Consult Pharm"},{"key":"19","article-title":"Safety and efficacy of standard and new antiepileptic drugs","volume":"55","author":"O Devinsky","year":"2000","journal-title":"Neurology"},{"key":"20","first-page":"343","article-title":"Adverse effects of antiepileptic drugs","volume-title":"Pediatric epilepsy - diagnosis and therapy","author":"L Willmore","year":"2001"},{"key":"21","article-title":"Valproate in the treatment of epilepsy in people with intellectual disability","volume":"42","author":"M Friis","year":"1998","journal-title":"J Intell Dis Res"},{"key":"22","first-page":"159","article-title":"Expert Consensus Guidelines Series: Treatment of psychiatric and behavioral problems in mental retardation","volume":"105","author":"A Rush","year":"2000","journal-title":"AJMR"},{"key":"23","article-title":"Carbamazepine in the treatment of epilepsy in people with intellectual disability","volume":"42","author":"H Waisburg","year":"1998","journal-title":"J Intell Dis Res"},{"key":"24","first-page":"629","article-title":"Cognitive side effects of antiepileptic drugs","volume-title":"Pediatric epilepsy - diagnosis and therapy","author":"A Aldenkamp","year":"2001"},{"key":"25","first-page":"555","article-title":"Drug interactions","volume-title":"Pediatric epilepsy\u2014diagnosis and therapy","author":"J Gilman","year":"2001"},{"key":"26","first-page":"1042","article-title":"Epilepsy","volume-title":"Pharmacotherapy\u2014a pathophysiologic approach","author":"B Gidal","year":"2002"},{"key":"27","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0920-1211(96)00072-1","article-title":"A decade of modern epilepsy therapy in institutionalized mentally retarded patients","volume":"25","author":"J Pellock","year":"1996","journal-title":"Epilepsy Res"},{"key":"28","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1097\/01376517-199612000-00003","article-title":"Clinical advocacy for persons with epilepsy and mental retardation living in community based programs","volume":"28","author":"J Baribeault","year":"1996","journal-title":"J Neurosci Nurs"}],"container-title":["The Consultant Pharmacist"],"original-title":[],"deposited":{"date-parts":[[2019,6,7]],"date-time":"2019-06-07T20:04:20Z","timestamp":1559937860000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.ingentaconnect.com\/content\/ascp\/tcp\/2004\/00000019\/00000006\/art00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,6,1]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2004,6,1]]}},"alternative-id":["4706365110032314"],"URL":"https:\/\/doi.org\/10.4140\/tcp.n.2004.524","relation":{},"ISSN":["0888-5109"],"issn-type":[{"value":"0888-5109","type":"print"}],"subject":[],"published":{"date-parts":[[2004,6,1]]}}}